title: Effect of anti-IL-4, interferon-gamma and an antifungal triazole (SCH 42427) in paracoccidioidomycosis: correlation of IgE levels with outcome.
abstract: Paracoccidioidomycosis is characterized by depressed cellular but enhanced humoral immune responses, which suggests a Th2 type of response to infection. We investigated possible therapeutic roles for anti-IL-4, interferon-gamma (IFN-gamma) and/or SCH 42427 (SCH), a new triazole antifungal agent, and their effect on serum IgE levels in a murine model of chronic Paracoccidioides brasiliensis infection. BALB/c mice infected by the pulmonary route were studied with three programmes. The subacute model and one acute model experiment investigated cytokine secretion by lymph node cells (LNC), and in a second acute experiment mice were given anti-IL-4, IFN-gamma or nothing 24 h post infection, then killed at 4 weeks. In the chronic model, mice began treatment at 4 weeks post infection, receiving either SCH, IFN-gamma alone, SCH+IFN-gamma, or no treatment for 8 weeks. At 2-week intervals lung and spleen burdens of infection and serum polyclonal IgE levels were determined. In the subacute model (non-progressive infection), initially there was dual production of IL-4 and IFN-gamma by antigen-stimulated LNC. In the acute progressive infection model IL-4, but not IFN-gamma, was secreted. Anti-IL-4 treatment of the acute phase resulted in enhanced host resistance to infection, which correlated with decreased serum IgE. The chronic model, in which the in vivo efficacy of SCH against P. brasiliensis was shown, suggests possible synergy between immunomodulation and antimicrobial chemotherapy (IFN-gamma and SCH). Decreased organ burdens of infection in the chronic model after treatment with SCH, SCH plus IFN-gamma, or anti-IL-4 correlated with decreased serum IgE. These promising novel approaches to treatment of systemic fungal infections suggest a Th2 type of response to P. brasiliensis infection, which can be reversed with successful therapy.
authors.affiliation: Department of Medicine, Santa Clara Valley Medical Centre, San Jose, CA 95128-2699.
authors.forename: J S
authors.initials: JS
authors.lastname: Hostetler
authors.forename: E
authors.initials: E
authors.lastname: Brummer
authors.forename: R L
authors.initials: RL
authors.lastname: Coffman
authors.forename: D A
authors.initials: DA
authors.lastname: Stevens
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D002908:Chronic Disease; D007073:Immunoglobulin E / Q000097:blood*; D007371:Interferon-gamma / Q000627:therapeutic use*; D015847:Interleukin-4 / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010229:Paracoccidioidomycosis / Q000276:immunology* / Q000628:therapy; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D000935:Antifungal Agents; D014230:Triazoles; C056513:Sch 39304; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma